drugset / Trial / NCT06695585

Optimal Intravesical Lidocaine Volume for Pain Relief During Office Intra-detrusor Onabotulinum Toxin a Injections

NCT06695585 ↗

Phase 4 Not yet recruiting 36 enrolled University of Louisville
RandomizedParallel-groupQuadruple-blindSupportive care

Summary

The purpose of our study is to evaluate the efficacy and safety of different volumes of bladder-numbing medication for pain relief at the time of office bladder Botox injections. This is a randomized prospective, double-blind superiority trial comparing 200 ml 2% lidocaine versus 30 ml 2% lidocaine for office Botox injections.

Timeline

Start
2024-12-01
Primary completion
2025-06-01
Completion
2025-12-01

Drugs

EvaluationDrugModalityDoseRoute
Comparator Lidocaine Other / unclassified 30 ml Intrathecal
Comparator Lidocaine Other / unclassified 200 ml Intrathecal

Indications